Management

Per Andersson

Chief Executive Officer

Chief Executive Officer at Xspray Pharma since 2006
Born 1967

Per has a background as Science Director at Gyros Protein Therapeutics AB, where he developed a completely new ground-breaking technology into something that is now profitable products. He has over 200 patents as an inventor and successfully worked in patent strategy for more than 25 years. Previously, he worked as a senior scientist at Cytiva AB, where he focused on technological innovation. Per is co-author of over 30 scientific publications.

Education: Ph.D. in Analytical Chemistry, Stockholm university

Other current activities: CEO of Xspray Pharma Inc., Chairman of the board of Robotic Lawn Care Sweden AB and Xspray Pharma Futurum AB, and deputy board member in Journeyman Stockholm AB

Previous assignments (recent 5 years): –

Holdings: 205,885 shares and 174,676 options of which 70,892 warrants and 103,784 employee stock options. 1,875 warrants TO6.

Independent in relation to the larger shareholders but not in relation to the company

Michael af Winklerfelt

Chief Financial Officer (Acting)

Chief Financial Officer at Xspray Pharma since 2024
Born 1972

Michael af Winklerfelt has long international experience from senior financial roles and also from serving as CFO for listed Life Science companies in Sweden

Education: M.B.A, Emory University. M.Sc. Business Administration, Stockholm School of Economics

Other current activities: Member of the Board of Ramén Valves

Previous assignments (the recent 5 years): –

Holdings in the Company: –

Independent in relation to major shareholders but not in relation to the Company

Anette Abrahamsson

Senior Vice President Regulatory Affairs

Senior Vice President Regulatory Affairs på Xspray Pharma since 2021
Born 1969

Anette has more than 25 years of experience from the pharmaceutical industry and has held positions within Regulatory Affairs, Drug Safety and Quality Assurance. Her experience reaches from Nordic to international responsibilities, within small and big pharmaceutical companies such as AstraZeneca, Pfizer, Unimedic Pharma, Karo Pharma and Cederroth. Anette has also had senior consultancy roles at Pharma Relations.

Education: M.Sc. Pharm, Uppsala University

Other current activities:

Previous board assignments (recent 5 years): –

Holdings in the Company: 1,500 shares and 28,612 options of which 12,722 warrants and 15,890 employee stock options. 175 warrants TO6.

Independent in relation to major shareholders but not in relation to the Company.

Linda Glimberg

Senior Vice President Legal

Senior Vice President, consultant, at Xspray Pharma since 2019
Born 1974

Linda has worked as a lawyer for more than 25 years of which more than 15 years as an in-house counsel at international companies. Since 2018 she has been running her own consultancy firm providing business legal advice, focusing on the life science sector. She has held various leading positions at AstraZeneca, Husqvarna and Keolis.

Education: Master of Laws (LLM), Uppsala University. Master of Laws (LLM) Cambridge University, England

Other current activities: Board Member of Robotic Lawn Care Sweden AB. Owner and Board Member of Glimberg Holding AB and Glimberg Consulting AB

Previous board assignments (recent 5 years): None

Holdings in the Company: 1,800 shares via Company. 200 warrants TO6 via Company.

Independent in relation to major shareholders but not in relation to the Company.

Kerstin Hasselgren

IR / Senior Advisor

Chief Financial Officer at Xspray Pharma since 2019
Born 1961

Kerstin Hasselgren has broad experience from working in large public international companies as VP Corporate Business Control at SSAB, CFO at Alstom Transport Nordic, VP Finance Global Operations at AstraZeneca and VP Finance Global R&D at AstraZeneca

Education: M.Sc. Business Administration, Stockholm School of Economics

Other current activities: Member of the Board of Synact Pharma

Previous assignments (the recent 5 years): –

Holdings in the Company: 8,248 shares and 82,750 options of which 40,250 warrants and 42,500 employee stock options. 916 warrants TO6.

Independent in relation to major shareholders but not in relation to the Company

Christer Hällgren

Senior Vice President Intellectual Property

Senior Vice President Intellectual Property at Xspray Pharma since 2018
Born 1962

Christer has more than 25 years of experience from the pharmaceutical industry.

Education: European Patent Attorney, Ph.D. Organic Chemistry, Stockholm University

Other current activities:

Previous board assignments (recent 5 years): None

Holdings in the Company: 29,996 shares and 50,310 options of which 25,770 warrants and 24,540 employee stock options. 5,777 warrants TO6.

Independent in relation to major shareholders but not in relation to the Company.
christer.hallgren@xspray.com

Edward Jordan

Chief Commercial Officer

Chief Commercial Officer at Xspray Pharma since 2023
Born 1967

Edward has extensive global biopharma commercial and operational experience having launched multiple products and commercial organizations.

Education: BS, Insurance and Finance, University of Rhode Island. MBA, Southern University of New Hampshire

Other current activities:

Previous board assignments (recent 5 years): –

Holdings in the company: –

Independent in relation to major shareholders but not in relation to the Company.

Charlotta Liljebris

Senior Vice President Research and Development

Senior Vice President Research and Development at Xspray Pharma since 2018
Born 1964

Charlotta Liljebris has 30 years of experience from the pharmaceutical industry. She has been responsible for the project portfolio and business development at Orexo, VP R&D at Aprea with focus on oncology and worked in several leading positions within project management at Biovitrum.

Education: Ph.D. in Medicinal Chemistry, Uppsala University, Sweden
M.Sc. in Chemistry, Uppsala University, Sweden

Other current activities:

Previous board assignments (the recent 5 years): Member of the Board in Recipharm OT Chemistry, Connect Uppsala and Sprint Bioscience

Holdings in the Company: 3,000 shares and 45,420 options of which 24,140 warrants and 21,280 employee stock options. 200 warrants TO6.

Independent in relation to major shareholders but not in relation to the Company.